INTRODUCTION
Standard forms of PDT involve the administration of an endogenous photosensitizer. This photosensitizer accumulates preferentially in malignant tissues and exposure to appropriate light wavelengths induces a phototoxic effect by producing active molecular species such as singlet oxygen (02) and free radicals 2. The advantage of photodynamic therapy (PDT) over conventional therapy is its dual selectivity 3. First, increased selectivity is obtained by localization of the photosensitizer in tumor, and secondly toxicity is limited to the irradiated area, thereby avoiding serious damage to adjacent normal tissue. However, it remains difficult to document this selectivity routinely in patients. Selectivity is not likely to occur in all patients since tumors are heterogeneous and could also be transient. The capability of monitoring sensitizer concentration in tissues is thus of considerable importance. If that compound can be induced to fluoresce when exposed to photons of appropriate wavelength, then it may be possible to identify the compound of interest because of its characteristic fluorescence emission or excitation spectrum and then to follow its synthesis andlor degradation in vivo by measuring changes in fluorescence intensity. In vivo spectrofluorometry laser technique appears to have significant advantages over other methods. It is highly sensitive and can record complete fluorescence emission spectra so rapidly that it is now feasible to obtain a series of such spectra in anesthetized or non-anesthetized animals. An alternative approach to sensitizer administration for PDT is to achieve photosensitizer synthesis in situ using a precursor that is either preferentially localized or preferentially converted to active photosensitizer by target tissue or cells. ALA is an endogenous substance which is converted to heme via PplX, an effective and well-known photosensitizer associated with the extreme skin phototoxicity seen in patients with porphyria 4p5,6.
The present study was designed to investigate the possibility of monitoring PplX fluorescence by the mean of a fiberoptic laser spectrofluorimeter designed in collaboration with INSERM U.281 (P.Lenz) after ALA injection We also tried to enhance fluorescence by modifying PplX concentration using the iron chelator desferrioxamine, also known as ~e s f e r a l~ ' , as well as EDTA an other metal chelator.
MATFRlAl S AND METHODS
2.1 Fluorescence spectrometer 488 nm light from an argon laser was used to excite fluorescence which was then.attenuated by reflection on a glass plate and fed into a 600 um core plasticclad silica fiber with perpendicular polished endfaces by means of a small 45" metal mirror and an achromatic lens. The distal fiber end was brought into direct contact with the target tissue. This system provides simultaneous delivery of excitation light and gathering of fluorescence light. Light leaving the fiber is imaged onto a glass fiber bundle (ORIEL 77402) through the above-mentioned achromatic lens, a second achromatic lens located behind the metal mirror and a high-pass filter (SCHOTT OG 530) which virtually eliminates backscattered laser light. The fiber bundle converts the circular beam into a rectangular one. Thus convenient spectral resolution is obtained when this system is coupled to the monochromator (JOBIN YVON CP 200). Spectra are recorded using a cooled 1024-element diode array and a 386 computer (with JOBIN YVON QUlKVlEW software). . The 488 nm line of an argon ion laser was used for excitation. Recording of a single spectrum took 20 ms, but we integrated over 3 s. Power density was 2 mW ~m -~ (488 nm). Light (excitation and reception) was then transmittted through a 600um silica silicon step index optic fiber.
Animals
Six-weeks-old NMRI hairless male nude mice (CERJ) weighing approximatively 30 g were used in this experiment. HT 29 tumor (human colic adenocarcinoma) was injected sub-cutaneously (0,2 ml of crushed tumor in solution in culture medium). All mice received a tumor graft [8] . Tumors were allowed to grow for 12 days until the experiment was performed. At that time, their mean diameter was 10 mrn (SD +/-2 rnm).
2.3. Chemicals 5-aminolevulinic acid (ALA) was obtained from Sigma Chemical Company (UK). Solutions containing 30, 60 or 90 mg of ALA per milliliter of isotonic saline were prepared immediately before use. 0,25 ml was injected intraperitoneally in order to reach final mouse concentrations of 250, 500 and 750 mgkg of body weight. All mice were kept in the dark until spectrofluorometry was performfd. De sf e rrioxamine was purchased in the lyophilized form of desferrioxamine mesylate (Desferal [DFO]) from CIBA-Geigy (Basel, Article published online by EDP Sciences and available at http://dx.doi.org/10.1051/jp4:1994447 Switzerland). This compound was administered subcutaneously to obtain concentrations of 20 and 40 mglkg of body weight. EDTA was obtained from Grosseron (GROSSERON S.A., Nantes, France) and administered subcutaneously to obtain concentrations of 10 and 20 mglkg of body weight.
2.4. Method Kinetic fluorometric studies were performed after administration of etheroxide inhalant at intervals of O; 30min; 6Omin; 90min; 2h; 3h; 4h and 6h and as well as in different tissues. We carried out measurements through the optic fiber placed directly in contact with the target. DFO and EDTA were injected subcutaneously 4 hours before ALA administration. Two, three and five hours after ALA injection, spectra were recorded directly in tissues. Thus, DFO or EDTA was injected at least 6 hours before spectrum recording. Muscle, turnor, liver, gall bladder, urinary bladder, kidney, heart and brain were successively studied. The same experimental conditions used to obtain sample material, anesthesic techniques and darkness were applied to the different groups. The fluorescence emission spectra of treated or untreated rnouse tissue weie recorded on 3 separite oicasions in order to estimate mouse-10-mouse variation.
3. RESULTS 3.1. In vivo PDIX fluorescence spectra after ALA iniection ~dministratio'n of a 250 rngkg ALA solution to rnice resulted in an increase in tissue fluorescence, with emission maxima at 632 nm and 702 nrn. All mice produced comparable PplX ernission spectra for ail tissues studied. The intensity of this fluorescence increased for approximatively 180 min in lung and kidney but for only 120 min in muscle and gall bladder gradually decreasing over a 3-h period. In addition, we noted an increased fluorescence emission at 545 nm in liver, gall bladder and urinary bladder. This ernission wavelength, typical of metabolized porphyrins such as bilirubin, was present in controls but increased after ALA injection. In controls receiving no ALA, 545 nm fluorescence was 30 ctsls in gall bladder and urinary bladder but increased after 60 min (gall bladder) and 360 min (urinary bladder) to a mean value of 168 and 101 cts/s respectively. 632 nm fluorescence was also found in the urinary bladder less than 240 min after ALA injection but then decreased (Fig 1C) . 
Changes in PplX fluorescence after ALA injection
Tmax and fluorescence intensities differed frorn one organ to another. In addition, in sorne organs fluore-cence increased and decreased in several phases. In heart, brain and lung, fluorescence intensity was rslatively low (about 10-25 cpsls) but in elirnination organs the fluorescence level was significantly higher, i.e. gall bladder with a recording of about 610 cpsls. (Table 2 ). In the first group, PplX fluorescence intensity increased in HT 29 adenocarcinorna, muscle, hearî and gall bladder, but the time required to reach maximum fluorescence was the sarne in these tissues as in mice injected withALA alone. In the second group, DFO 20 or 40 mglkg induced only slight changes in ALA-stimulated porphyrin production which was even somewhat decreased cornpared, tolhat of controls. However, in liver there was a shorter interval after ALA administration before maximal fluorescence was reached. In kidney and brain, on the contrary, Trnax was shifted to 5 h with DFO instead of 3 h as in controls. In the urinary bladder, both Tmax and fluorescence intensity were changed for DFO 40 rnglkg. The PplX fluorescence intensity induced by ALA increased after DFO administration, and there waç a shorîening of the Trnax shifting frorn 5h to 3 h. After DFO 20 mglkg, fluorescence intensity increased, but the kinetic was similar to that of controls. Trnau: Time w h e n f l u o r e s c e n c e i n t e n s i t y i s mauirnel r i n c e ALR i n j e c t i o n .
intenrity. !/lm: l n t e n s i t y r e c o r d e d i n t h e t i s s u e a f t e r chernical a d m i n i s t r a t i o n / background i n t e n s i t y i n t i s s u e studied. PplX fluorescence intensity to a non-significant level. ln liver, fluorescence intensity was lower with EDTA and ALA than with ALA alone. However, fluorescence remained easily detectable. In Iiver and gall bladder, although Tmax were unchanged, maximum fluorescence decreased for 10 mglkg but increased for 20 mglkg. Tumor tissues showed a Tmax identical to controls but minimum fluorescence with 10 mglkg and then increased amounts. EDTA decreased Tmax and fluorescence intensity in kidney and urinary bladder.
DISCUSSION
We designed a laser spectrofluorometer to measure tissue sensitizer concentration since PDT efficacy is at least partly concentration-related. A new means of PDT sensitization was studied, involving administration of ALA to induce endogenous porphyrin synthesis. Kinetic studies of porphyrin biosynthesis in mouse tissues are presented as examples of the potential usefulness of the spectrofluorometer.
As ALA is non-or weakly fluorescent, the emission spectrum is related to the fluorescent material that appears in the mouse tissues after systemic administration which is thought to be PplX.
This study showed a strong correlation between the intensity and location of ALA-induced PplX fluorescence. In the absence of significant concentrations of quenching substances, that cell will begin to develop PplX fluorescence and also will become photosensitized 11 11. However, tissues such as liver may contain a high concentration of PplX fluorescence but emit little because of internal quenching of the fluorescence. All of this indicates why fluorescence depends greatly on the organ involved as well as the beside ALA dose or the internal after injection.
We investigated the distribution of ALA-induced porphyrin fluorescence at various intervals after introduction of ALA, both in normal and tumor tissue in the mouse. Divaris et al. 9 have shown that the intensity of ALA-induced PplX fluorescence in tissue after systemic administration of ALA to mice is correlated with the amount of phototoxic damage. Maximum fluorescence is rapidly obtained with nearmaximal tissue levels of PplX reached at 23h. We also demonstrated a significant advantage of ALA-induced porphyrin over conventional sensitisers in that the sensitization level returns to nearly background fluorescence after 6 hours, except in urinary bladder, gall bladder and liver.
Modulation of ALA-induced porphyrin synthesis is also of interest as a means of eventually increasing PplX concentration in tumors. Since desferrioxamine (DFO) is used as a therapeutic iron chelator in humans, we investigated whether tetrapyrrol synthesis may be stimulated in mammalian cells by DFO iron trapping. DFO is reported to be a very potent stimulator of ALA-driven photosensitization in vitro. In Our study, DFO or EDTA administration before ALA injection induced no significant increase in PplX fluorescence but rather an inhibitory action on ALA-induced PplX fluorescence. In addition, it seemed to us that DFO and EDTA induced modifications in elimination pathways of endogenously synthetized porphyrins.
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